20 / 29
Euro Gastroenterology 2019 & Clinical Pharmacy 2019
Archives of General Internal Medicine | ISSN: 2591-7951 | Volume 3
Page 41
March 25-26, 2019 | Amsterdam, Netherlands
&
GASTROENTEROLOGY AND HEPATOLOGY
4
th
International Conference on
CLINICAL PHARMACY & PHARMACY PRACTICE
9
th
World Congress on
Joint Event on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
alliedacademies.comYEARS
TREATMENT OUT COME AND SIDE EFFECTS OF DIRECTLY ACTING ORAL ANTI
HCV DRUGS A SINGLE CENTER EXPERIENCE
Abdul Qadir Khan
Mohammad Medical College Hospital, Pakistan
Objective:
To see treatment outcome and side-effects of directly acting oral anti HCV drugs.
Study Designs:
Single prospective / observational study.
Place and duration of study:
Liver & GI center new towns Mirpurkhas from August 2017 to August 2018.
Inclusion criteria:
All chronic hepatitis C patients.
Exclusion criteria:
Pregnancy, Lactating females and Hepatocellular Carcinoma.
Methodology:
Outdoor chronic Hepatitis C patient treated with directly acting oral anti HCV drugs were en-
rolled. Quantitative HCV RNA was tested at week 4, 12 during and week 24 after the treatment, side effects of
treatment were asked from the patients during the follow up visits. Data was put on a pre designed performa
Results:
94 numbers of patients enrolled, out of which 48 were males and 47 were females, male to female ratio
was 1:1. 51 (52%) were naive, 47 (47.9 %) were treatment experienced, out of them 32 (32.6%) were CLD patients,
out of them 22 (68.3%) were child A cirrhosis, 10 (31%) were child B cases. One patient was co-infected with HBV;
their previous treated genotype was 3a (68%). Quantitative PCR ranges from 1020 IU to 530000 IU/ml.
In all (94) patients HCV RNA was negative at 4 and 12 weeks of treatment. Viral response at 24 weeks after the
treatment was different. Viral clearance in patients With Sofosbuvir and Ribavirin was 83% (50 out of 62). With
Sofosbuvir and Daclatasvir response rate was 91% (11 out of 12). One patient put on Sofosbuvir and Ribavirin
stop the treatment by herself due to palpitation and epigastric pain.
While in decompensated patients put on Sofosbuvir and Ribavirin the response rate was 65 % (13 out of 20), and
patients put on Sofosbuvir and Ribavirin and Daclatasvir the response rate was 83% (10 out of 12). One cirrhotic
patient developed HCC during the treatment may be due to disease course not because of the treatment. Mild
anemia was noted in 15 numbers (14.7%) of patients that was treated with folic acid and iron, no major side of the
DAAs were noted during the treatment.
Conclusion:
New directly acting oral anti HCV (DAAs) is well tolerated and efficacious, further studies are needed
in more number of patients to assess the efficacy and side effects.
Abdul Qadir Khan, Arch Gen Intern Med 2019, Volume 3 | DOI: 10.4066/2591-7951-C1-023